Monthly Communication Report

Organization:	MS Canada/SP Canada
Associated registration:	935976-14937-83
Communication date:	2026-03-02
Posted date:	2026-04-17

Designated Public Office Holders who participated in the communication:	Maggie Chi, Member of Parliament House of Commons Marjorie Michel, Minister of Health House of Commons Karim Bardeesy, Member of Parliament House of Commons Kody Blois, Member of Parliament House of Commons Ryan Turnbull, Member of Parliament House of Commons Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions Innovation, Science and Economic Development Canada (ISED) Mark Carney, Prime Minister Prime Minister's Office (PMO) Rechie Valdez, Member of Parliament House of Commons Carlos Leitão, Member of Parliament House of Commons Rachel Bendayan, Member of Parliament House of Commons Wayne Long, Secretary of State Canada Revenue Agency (CRA) Leslie Church, Member of Parliament House of Commons Patty Hajdu, Minister of Jobs and Families House of Commons François-Philippe Champagne, Minister of Innovation, Sciences and Economic Development Minister's Office, Innovation, Science and Economic Development Canada (ISED) Annie Koutrakis, Member of Parliament House of Commons
List of Details Subject matter Detail Budget, Health, Research and Development, Taxation and Finance Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare. Budget, Health, Research and Development, Taxation and Finance Bill C-64, An Act Respecting Pharmacare with respect for persons with MS and other chronic conditions and disabilities Budget, Health, Housing, Taxation and Finance Canada Health Act and regulations, as it relates to long-term and home care Budget, Employment and Training, Health, Pensions, Taxation and Finance Canada Pension Plan – Disability with respect to eligibility for persons with MS and other chronic and episodic disabilities Budget, Employment and Training, Health, Housing, Pensions, Taxation and Finance Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities Budget, Health, Taxation and Finance Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities Budget, Employment and Training, Health, Taxation and Finance Employment Insurance sickness benefits, with respect to creation of flexible benefits for persons with MS and other episodic disabilities Budget, Employment and Training, Health, Housing, Labour, Pensions, Research and Development, Science and Technology, Taxation and Finance, Transportation Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS. Budget, Health, Housing, Taxation and Finance Home care, with respect to creation with provincial/ territorial governments programs relating to increased home care for persons with MS and other disabilities/ diseases and the support of caregivers Budget, Health, Research and Development, Science and Technology, Taxation and Finance We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV).
Responsible Officer who filed this communication report:	Pamela Valentine
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.